Did you get in on this? If not, it’s not too late.

Brickell Analytics correctly predicted  a 362% move in Opko. On March 29th when Opko (OPK) was $1.40, we said it would bottom at $1, and then surge to $10. On April 3rd, OPK bottomed at $1.1171. Since then, OPK has rallied and hit a 52 week high of $6.47. See our analysis below

What if Covid-19 is more contagious, but less deadly than the flu? / Did Coronavirus arise from Influenza C?

Commentary and charts attached highlights below:
  • Our background explained
  • COVID-19 Structure
  • Is Coronavirus similar to the Influenza C?
  • What if Covid-19 is that mild influenza C that does indeed cause a human flu pandemic with a lower mortality rate than the regular flu?
  • So the problem is not Corona, but the actual measures taken to fight Corona and whether the wave of pessimism that started at the record-highs can be reversed
  • Standardizing Covid-19 testing could become big business for OPK

Corona vs Influenza C

By way of background, in 2002, we launched a time-release nutritional supplements business in collaboration and partnership with a Swiss company. We researched, formulated, and developed approximately two dozen products in timed-release pill form and we also conducted bioavailability studies on some of these formulations. In 2013, we evolved the company into a research organization whose objective is to study the effects of nutritional supplements in-vitro against pathogens and human cancer cell lines. Between 2013 and 2016, we conducted six in-vitro studies: one at a lab in Tustin, CA and the other five at a lab in Birmingham, AL. In our first study in California, our objective was to determine whether riboflavin was a bacteriostatic agent. In our five in-vitro studies in Birmingham, we successfully burst six different human cancer cell lines using various different nutritional supplements, some proving to be stronger than others.

Book an Appointment with Isaac Gilinski – Brickell Analytics, LLC

Isaac Gilinski is the Founder and Head of Research for Brickell Analytics LLC, a global-macro research service based on contrarian analysis. The firm, established in 2011, has programmed two quantitative models with a nine-year track record, one on the S&P 500 and the other one on oil. Our second service is comprised of technical commentary that uses the handwriting technique on charts to forecast the direction of the macro markets. The forecast combines Elliott waves, sentiment, Fibonacci retracements and extensions, and proprietary tools (see theories & indicators) to generate price targets. Brickell Analytics’ research has been used and is used by hedge fund managers, investors, family offices, mutual funds, registered reps, and registered investment advisers.

Brickell Analytics’ trade ideas are executed in a fund or in SMAs at Broadmark Asset Management LLC, a top-down macro manager that rejects traditional buy and hold investing. Since 1999, Broadmark has tactically adjusted equity market exposure avoiding the two major drawdowns.